Nature Italy is published independently by Nature Portfolio, part of Springer Nature. Nature Portfolio is responsible for managing the editorial team and setting the editorial agenda.
Nature Italy is produced with financial support from a consortium of partners. Nature Portfolio acknowledges the support of Kedrion Biopharma, Farmindustria and IRCCS Ospedale San Raffaele. Nature Portfolio has sole responsibility for all editorial content About supported content.
Messages from our sponsors.
Farmindustria is the association representing 200 Italian and foreign-owned pharmaceutical companies operating in Italy. Founded in 1978, it is a member of Confindustria, the General Confederation of Italian Industry, of EFPIA, the European Federation of Pharmaceutical Industries and Associations, and of IFPMA, the International Federation of Pharmaceutical Manufacturers and Associations.
Farmindustria has adopted a Code of Conduct – one of the most severe in Europe – to regulate inter-company dealings and relations with the scientific and healthcare communities.
It works in close cooperation with national authorities to ensure a stable regulatory framework and pharmaceutical policies that acknowledge the vital role played by the industry in the socio-economic growth in the country. The association promotes events and activities throughout the nation to raise the awareness of the importance of this sector also at the local level, and to allow the wider public - students in particular - to become familiar with the world of life sciences and innovation. Much attention is given to corporate welfare, especially to the life-work balance of employees.
Pharma companies operating in Italy play a strategic role in the Country and in Europe, as Italy is a hub for production with an important role for R&D. With more than 66,500 staff in 170 sites, the pharmaceutical production in Italy amounts to about 2% of Italy’s GDP.
Kedrion Biopharma is an international biopharmaceutical company that collects and fractionates plasma to produce and distribute worldwide plasma-derived products for the prevention and treatment of rare and debilitating diseases and conditions such as hemophilia, primary immunodeficiencies and Rh sensitization.
Headquartered in Tuscany and with more than 2,700 employees worldwide, Kedrion has a commercial presence in 100 countries and is the fifth largest player in the world, and the first in Italy.
Kedrion has manufacturing plants in Italy, the United States and Hungary, and its subsidiary KEDPLASMA operates plasma collection centers in the United States and Hungary.
Kedrion is a long-standing partner of the Italian National Health System, which it concretely supports in the pursuit of self-sufficiency in the supply of plasma-derived products.
Because of its roots as a mainly family business, Kedrion places a high value on the welfare of those who benefit from its products, as well as the communities and individuals with whom it works and collaborates.
Kedrion acts as a bridge between donors and the people who need treatments, and works on a global scale to expand patient access to available plasma-derived therapies.
IRCCS Ospedale San Raffaele is a university hospital and scientific institute established in 1971 to provide specialized care for the most complex health conditions and to perform cutting-edge translational research. Ospedale San Raffaele was first recognized by the Italian Ministry of Health as a research hospital in 1972 for its expertise in diabetes research and cure. The recognition as IRCCS was then extended to the entire field of molecular medicine in 2001. Thanks to 100 high-tech laboratories and pre-clinical facilities, 50 medical specialties, 50.000 hospitalizations per year and more than 880 ongoing clinical trials, at Ospedale San Raffaele basic science translate quickly into clinical practice and clinical needs drive basic research.
Since May 2012, Ospedale San Raffaele joined Gruppo Ospedaliero San Donato, the leading Italian hospital group.
A translational approach
IRCCS Ospedale San Raffaele integrates basic and clinical research through a translational approach, in which lab discoveries translate quickly into clinical therapies and clinical needs drive basic research. The institute aims at understanding the mechanisms underlying a variety of human diseases and at identifying new targets and therapeutic strategies to treat them. Among the principal clinical area of investigation: central and peripheral nervous systems pathologies, tumors, immuno-mediated, infectious, genetic, cardiovascular and metabolic diseases. Alongside with improving therapies, the institute seeks to develop new technologies in the field of genomics and imaging, needed for early diagnosis and personalized cures. The Institute is recognized as a global authority in cell and gene therapies, and is at the forefront of research in many other field.